Stocks:
5,472
ETFs:
2,400
Exchanges:
11
Market Cap:
$57.88T
24h Vol:
$10.25B
Dominance:
MSFT:5.17%
Stocklytics Platform
BETA
Instrument logo  ERNA

Eterna Therapeutics Inc.

ERNA
38 / 100
Penny Stock
$1.64arrow_drop_down-1.49%-$0.02

Performance History

Stocklytics logo
Key Stats
Open$1.67
Prev. Close$1.67
EPS-3.96
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
Market Cap8899992.85
PE Ratio-
LOWHIGH
Day Range1.55
1.67
52 Week Range0.84
4.04
Ratios
P/B Ratio2.54
Revenue-
Operating M. %-10,794.12%
Earnings$0.00
Earnings Growth %18.61%
EBITDA Margin %-
ROE %-323.30%
EPS-3.96

Score Breakdown

38vs 52. Market Avg.

All Score 38 / 100 is to help users identify stocks that trade at a low value relative to their fundamentals. Suitable for value investors such as Warren Buffet.

ERNAMARKET
Value5639
Quality2740
Ownership2319
Growth2645
Dividends-38
check_circle

Eterna Therapeutics Inc.'s Price discount from all time high of 99.99% is great compared to market average of 40.91%. This indicates ERNA could be a good value stock.

Financial Forecast

AI Price Prediction

line chart placeholder

Analyst Ratings

Analyst ratings for this stock instrument are based on analysts' assumptions and should not be solely relied upon for financial decisions.

Correlated Companies

PRICE$755.71
24H (%)arrow_drop_down-3.36%
24H ($)-$26.35
MARKET CAP$717.31B
PRICE$520.43
24H (%)arrow_drop_down-0.21%
24H ($)-$1.11
MARKET CAP$481.41B
PRICE$157.70
24H (%)arrow_drop_up0.73%
24H ($)$1.14
MARKET CAP$379.86B
PRICE$128.06
24H (%)arrow_drop_up0.21%
24H ($)$0.27
MARKET CAP$324.50B

About Eterna Therapeutics Inc. (ERNA)

Eterna Therapeutics Inc., a preclinical-stage, biopharmaceutical company. The company offers Synthetic mRNA, ToRNAdo mRNA Delivery, mRNA Gene Editing, and mRNA Cell Reprogramming. It also develops therapies and medicines using gene-editing proteins and cell therapy technology for the treatment of oncology, blood disorder, and monogenic disease. The company was formerly known as Brooklyn ImmunoTherapeutics, Inc. and changed its name to Eterna Therapeutics Inc. in October 2022. Eterna Therapeutics Inc. is based in Cambridge, Massachusetts.

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Matthew Angel Ph.D.
Headquarters
Cambridge
Employees
9
Exchange
NASDAQ
add Eterna Therapeutics Inc. to watchlist

Keep an eye on Eterna Therapeutics Inc.

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
question_mark
What is Eterna Therapeutics Inc.'s (ERNA) price per share?

The current price per share for Eterna Therapeutics Inc. (ERNA) is $1.64. The stock has seen a price change of -$0.02 recently, indicating a -1.5% change. This reflects the stock's recent market performance and investor sentiment.

question_mark
What is the 52-week high and low for Eterna Therapeutics Inc. (ERNA)?

For Eterna Therapeutics Inc. (ERNA), the 52-week high is $4.04, which is 145.59% from the current price. The 52-week low is $0.84, the current price is 95.83% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

question_mark
Is Eterna Therapeutics Inc. (ERNA) a growth stock?

Eterna Therapeutics Inc. (ERNA) has shown an average price growth of -75.07% over the past three years. It has received a score of -10 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Eterna Therapeutics Inc. as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

question_mark
What is Eterna Therapeutics Inc. (ERNA) stock price performance year to date (YTD)?

As of the latest data, Eterna Therapeutics Inc. (ERNA) has a year-to-date price change of -12.5%. Over the past month, the stock has experienced a price change of 14.09%. Over the last three months, the change has been 50.92%. Over the past six months, the figure is -31.46%.

question_mark
Is Eterna Therapeutics Inc. (ERNA) a profitable company?

Eterna Therapeutics Inc. (ERNA) has a net income of -$20M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -10.79K% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , although specific revenue growth data is currently not available. Operating income is noted at -$20.57M. Furthermore, the EBITDA is -$20.34M.

question_mark
What is the market capitalization of Eterna Therapeutics Inc. (ERNA)?

Eterna Therapeutics Inc. (ERNA) has a market capitalization of $8.9M. The average daily trading volume is 5.53K, indicating the stock's liquidity and investor engagement.

email

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Approach investments with caution like a driver who slows down on a curvy road.